0001641172-25-003085.txt : 20250407 0001641172-25-003085.hdr.sgml : 20250407 20250407213745 ACCESSION NUMBER: 0001641172-25-003085 CONFORMED SUBMISSION TYPE: SCHEDULE 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250407 DATE AS OF CHANGE: 20250407 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Dermata Therapeutics, Inc. CENTRAL INDEX KEY: 0001853816 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-92822 FILM NUMBER: 25819982 BUSINESS ADDRESS: STREET 1: 3525 DEL MAR HEIGHTS RD., #322 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858)-223-0882 MAIL ADDRESS: STREET 1: 3525 DEL MAR HEIGHTS RD., #322 CITY: SAN DIEGO STATE: CA ZIP: 92130 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: PROEHL GERALD T CENTRAL INDEX KEY: 0001279191 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13D/A BUSINESS ADDRESS: STREET 1: 10590 W OCEAN AIR DR STREET 2: STE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 8583145700 SCHEDULE 13D/A 1 primary_doc.xml SCHEDULE 13D/A 0000905718-21-001150 0001279191 XXXXXXXX LIVE 7 Common Stock, Par Value $0.0001 Per Share. 03/27/2025 false 0001853816 249845405 Dermata Therapeutics, Inc.

3525 Del Mar Heights Rd., #322 San Diego CA 92130

Gerald T. Proehl (973) 701-2431 President and Chief Executive Officer 3525 Del Mar Heights Rd., #322 San Diego CA 92130 0001279191 N PROEHL GERALD T PF N X1 804098.00 0.00 804098.00 0.00 804098.00 N 13.3 IN See Item 5 for additional information. 0001877913 N Proehl Investment Ventures LLC WC N CA 799624.00 0.00 799624.00 0.00 799624.00 N 13.3 IN See Item 5 for additional information. Common Stock, Par Value $0.0001 Per Share. Dermata Therapeutics, Inc. 3525 Del Mar Heights Rd., #322 San Diego CA 92130 This Amendment No. 7 (this "Amendment") amends and supplements the Schedule 13D filed on behalf of the Reporting Persons with the Securities and Exchange Commission on August 27, 2021, as amended on April 25, 2022, January 13, 2023, March 30, 2023, January 23, 2025 February 13, 2025 and April 3, 2025 (collectively, the "Schedule 13D"). Except as specifically provided herein, this Amendment does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. This Amendment is being filed solely to correct the number of the Issuer's shares of Common Stock outstanding and percentage of securities beneficially owned by the Reporting Persons as of the date hereof, which was incorrectly reported in Amendment No. 6, filed on April 3, 2025, and not as a result of any transaction in the securities of the Issuer. The information contained in rows 7, 8, 9, 10, 11 and 13 of the cover pages of this Schedule 13D and the information set forth in or incorporated by reference in Item 2 and Item 3 of the Schedule 13D is hereby incorporated by reference in its entirety into this Item 5. As of the date hereof, Mr. Proehl may be deemed to beneficially own an aggregate of 804,098 shares of Common Stock reported herein as follows: (i) 247 shares of Common Stock and stock options to purchase 2,777 shares of Common Stock held directly by Mr. Proehl; (ii) 799,508 shares of Common Stock and warrants to purchase up to 116 shares of Common Stock held directly by Proehl Investment Ventures LLC ("PIV"); (iii) 855 shares of Common Stock and warrants to purchase up to 595 shares of Common Stock held in the aggregate by certain trusts (the "Trusts") for which Mr. Proehl is trustee. Mr. Proehl's reported ownership excludes (i) 50,556 shares of Common Stock underlying stock options held by Mr. Proehl that will not vest as to such shares of Common Stock within sixty (60) days of the date hereof, and (ii) 787,402 shares of Common Stock underlying a warrant that is not exercisable within sixty (60) days of the date hereof. As a result of the foregoing, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Mr. Proehl may be deemed to beneficially own 13.3% of the Common Stock of the Issuer outstanding as of the date hereof (based on 6,032,648 shares of Common Stock outstanding as of March 27, 2025 based on information obtained from the Issuer). As of the date hereof, PIV may be deemed to be the beneficial owner of an aggregate of 799,624 shares of Common Stock reported herein as follows: (i) 799,508 shares of Common Stock and (ii) warrants to purchase up to 116 shares of Common Stock. As a result of the foregoing, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, PIV may be deemed to beneficially own 13.3% of the Common Stock of the Issuer outstanding as of the date hereof (based on 6,032,648 shares of Common Stock outstanding as of March 27, 2025 based on information obtained from the Issuer). As of the date hereof, Mr. Proehl may be deemed to be the beneficial owner of an aggregate of 804,098 shares of Common stock, all of which he has sole voting and dispositive power. As of the date hereof, PIV may be deemed to be the beneficial owner of an aggregate of 799,624 shares of Common stock, for all of which voting and dispositive power is held by Mr. Proehl, as PIV's managing member. During the sixty (60) days on or prior to March 27, 2025, there were no purchases or sales of shares of Common Stock, or securities convertible into or exchangeable for shares of Common Stock, by the Reporting Persons or any person or entity for which the Reporting Persons possess voting or dispositive control over the securities thereof. None. Not applicable. PROEHL GERALD T /s/ Gerald T. Proehl 04/07/2025 Proehl Investment Ventures LLC /s/ Gerald T. Proehl 04/07/2025